Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 7 | 2024 | 1192 | 0.670 |
Why?
|
| Graft vs Host Disease | 4 | 2024 | 542 | 0.590 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 53 | 0.500 |
Why?
|
| Transplantation Conditioning | 4 | 2018 | 322 | 0.480 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 230 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 223 | 0.430 |
Why?
|
| Anemia, Sickle Cell | 3 | 2024 | 333 | 0.420 |
Why?
|
| Unrelated Donors | 4 | 2024 | 81 | 0.380 |
Why?
|
| Factor VIIa | 1 | 2010 | 23 | 0.350 |
Why?
|
| Pulmonary Alveoli | 1 | 2010 | 139 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 4 | 2024 | 581 | 0.290 |
Why?
|
| Hemorrhage | 1 | 2010 | 457 | 0.270 |
Why?
|
| Lung Diseases | 1 | 2010 | 384 | 0.270 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2021 | 98 | 0.190 |
Why?
|
| Immune Reconstitution | 1 | 2018 | 6 | 0.160 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.150 |
Why?
|
| Thalassemia | 1 | 2018 | 11 | 0.150 |
Why?
|
| Hemoglobinopathies | 1 | 2015 | 16 | 0.130 |
Why?
|
| Exercise | 1 | 2021 | 749 | 0.120 |
Why?
|
| Mucolipidoses | 1 | 2014 | 7 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1994 | 318 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1103 | 0.110 |
Why?
|
| Burkitt Lymphoma | 2 | 2005 | 146 | 0.110 |
Why?
|
| Mason-Pfizer monkey virus | 3 | 1998 | 3 | 0.100 |
Why?
|
| Endopeptidases | 3 | 1998 | 115 | 0.090 |
Why?
|
| Instillation, Drug | 1 | 2010 | 7 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 1994 | 973 | 0.090 |
Why?
|
| Gene Expression | 2 | 1995 | 1592 | 0.090 |
Why?
|
| Escherichia coli | 2 | 1995 | 981 | 0.080 |
Why?
|
| Humans | 15 | 2024 | 122423 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2010 | 155 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 659 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 1403 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2018 | 1472 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2004 | 803 | 0.070 |
Why?
|
| Child | 7 | 2018 | 24118 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2004 | 122 | 0.070 |
Why?
|
| Male | 8 | 2018 | 59600 | 0.060 |
Why?
|
| Gingivitis, Necrotizing Ulcerative | 1 | 2005 | 1 | 0.060 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2005 | 8 | 0.060 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2004 | 13 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2005 | 86 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 64 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 871 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2018 | 12036 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2003 | 85 | 0.050 |
Why?
|
| Fusarium | 1 | 2003 | 11 | 0.050 |
Why?
|
| Female | 9 | 2018 | 64961 | 0.050 |
Why?
|
| Mycoses | 1 | 2003 | 116 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 773 | 0.050 |
Why?
|
| Bacteremia | 1 | 2005 | 405 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 18984 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1998 | 355 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 122 | 0.040 |
Why?
|
| Retroviridae Proteins | 1 | 1998 | 13 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1119 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1995 | 189 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2018 | 13840 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2018 | 178 | 0.030 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 28 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 522 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1995 | 900 | 0.030 |
Why?
|
| Infant | 4 | 2018 | 12347 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 186 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 1995 | 53 | 0.030 |
Why?
|
| Siblings | 1 | 2015 | 193 | 0.030 |
Why?
|
| DNA Restriction Enzymes | 1 | 1994 | 121 | 0.030 |
Why?
|
| Protein Precursors | 1 | 1994 | 150 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 1265 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 2701 | 0.030 |
Why?
|
| Bacteriophages | 1 | 1994 | 79 | 0.030 |
Why?
|
| Plasmids | 1 | 1994 | 516 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 383 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3888 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2015 | 498 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 2001 | 0.020 |
Why?
|
| Base Sequence | 1 | 1994 | 3119 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4987 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 1250 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 78 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 2005 | 58 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2004 | 23 | 0.010 |
Why?
|
| Prognosis | 2 | 2004 | 4492 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 3613 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2004 | 25 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 50 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2004 | 43 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2004 | 84 | 0.010 |
Why?
|
| Immunoconjugates | 1 | 2004 | 35 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2004 | 235 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 301 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 338 | 0.010 |
Why?
|
| Voriconazole | 1 | 2003 | 35 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2004 | 298 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2004 | 177 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 237 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2003 | 90 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2003 | 333 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2004 | 319 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 752 | 0.010 |
Why?
|
| Triazoles | 1 | 2003 | 137 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2004 | 421 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 261 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 810 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1092 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2003 | 374 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 1293 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2004 | 661 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1998 | 18 | 0.010 |
Why?
|
| Haplorhini | 1 | 1998 | 127 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1998 | 284 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1998 | 424 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 3300 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1998 | 620 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 1431 | 0.010 |
Why?
|
| Isopropyl Thiogalactoside | 1 | 1995 | 4 | 0.010 |
Why?
|
| HIV Protease | 1 | 1995 | 5 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1995 | 22 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1995 | 96 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1679 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1995 | 186 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 393 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 1995 | 90 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 5974 | 0.010 |
Why?
|
| Animals | 1 | 1998 | 33897 | 0.000 |
Why?
|